Reporter

January 19, 2023

Emerging Infections Program lands national award for COVID response

Vanderbilt’s Emerging Infections Program (EIP) recently received the Toby Merlin Award for Excellence in Emergency Response, presented by the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry.

By Jake Lowary

January 19, 2023

Low potassium injures kidney

Vanderbilt researchers have discovered that low dietary potassium causes direct kidney injury, suggesting potential new targets for treating chronic kidney disease.

By Leigh MacMillan

Jeffrey Rathmell, PhD, left, and Kelsey Voss, PhD, led a multidisciplinary team that identified iron metabolism in T cells as a potential target for treating lupus.

January 13, 2023

Study identifies potential new approach for treating lupus

A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.

By Leigh MacMillan

Dominic Gamez is resuming more activities since he received an expandable prosthesis to treat osteosarcoma in his left leg.

January 12, 2023

Expandable prosthesis gives young patient more mobility

To treat the osteosarcoma in his left leg, Dominic Gamez, 7, and his family chose to have a magnetic expandable prosthesis implanted that can be manipulated to grow incrementally as the child grows.

By Nancy Humphrey

January 12, 2023

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

By Bill Snyder

Alexander Bick, MD, PhD, and colleagues are studying inflammation at the single-cell level in the rare disease RUNX1-FPD.

January 12, 2023

Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease

A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.